vida: extract claims from 2025-xx-pmc-glp1-eating-disorders-double-edged-sword

- Source: inbox/queue/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "Developmental timing creates a double exposure: adolescence is both the peak ED onset period and the demographic with highest social media use driving cosmetic GLP-1 demand"
+confidence: experimental
+source: PMC/Journal of Clinical Medicine systematic narrative review, 2025
+created: 2026-05-04
+title: Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
+agent: vida
+sourced_from: health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
+scope: causal
+sourcer: PMC / Journal of Clinical Medicine
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+---
+
+# Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
+
+The review identifies adolescents as the highest-risk population for GLP-1-induced eating disorder harm through a developmental timing mechanism. Two factors converge: (1) eating disorder prevalence peaks during adolescence, creating a large vulnerable population, and (2) adolescent social media use is highest, maximizing exposure to cosmetic GLP-1 promotion. This creates a compounding risk structure where the population most vulnerable to eating disorder onset is also most exposed to the cultural messaging that drives cosmetic GLP-1 misuse. The review explicitly names adolescents as an at-risk population requiring special consideration, alongside patients obtaining GLP-1s for cosmetic purposes without medical supervision and individuals with prior ED history. This is distinct from general GLP-1 eating disorder risk because it identifies a specific demographic where two independent risk factors (developmental vulnerability + cultural exposure) multiply rather than add.

domains/health/glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal.md

@@ -17,3 +17,10 @@ related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-res
 # No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
 
 This review explicitly confirms that evidence for GLP-1 receptor agonists in anorexia nervosa (AN) is 'extremely limited' with theoretical risks rather than empirical data. The paper states that risks for restrictive eating disorders include 'appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules' but provides no RCT citations for these outcomes. This creates a critical evidence gap: pharmacovigilance systems show elevated eating disorder risk (VigiBase aROR 4.17-6.80), clinical guidelines recommend pre-treatment eating disorder screening, yet no prospective trials have tested GLP-1 safety or efficacy in patients with restrictive eating disorder histories. The absence of trial evidence means that current prescribing occurs without subtype-specific risk stratification. The review notes that benefits for BED (reduced binge episodes) 'may not persist long-term,' suggesting that even for the eating disorder subtype with positive theoretical rationale, durability is uncertain. This evidence vacuum is particularly concerning given that the review recommends 'rigorous monitoring until long-term safety in diverse populations established' while acknowledging that such monitoring infrastructure does not currently exist in standard prescribing practice.
+
+
+## Supporting Evidence
+
+**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
+
+Review confirms 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders, while simultaneously documenting case evidence and calling for longer-term follow-up studies (up to 5 years) to detect delayed ED symptom onset.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -17,3 +17,10 @@ related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesoli
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
 
 This review establishes that GLP-1 receptor agonists create opposing clinical outcomes across eating disorder subtypes through a single pharmacological mechanism. For binge eating disorder (BED), GLP-1 RAs reduce binge episodes by modulating mesolimbic dopamine circuits that drive reward-based eating. However, for restrictive eating disorders (anorexia nervosa, atypical AN), the same appetite suppression mechanism that benefits BED patients can reinforce existing restriction patterns by enhancing satiety signals in individuals already predisposed to under-eating. The paper notes that evidence for anorexia nervosa is 'extremely limited' with theoretical risks including 'appetite suppression masking restrictive behaviors' and 'reinforcement of maladaptive food rules.' This creates a clinical paradox where the drug's core mechanism of action is therapeutic for one eating disorder subtype and potentially iatrogenic for another. The review identifies highest-risk populations as individuals with restrictive eating disorder histories, those with high perfectionism or OCD traits, adolescents during critical development, and racial/ethnic minorities facing intersectional stigma. This mechanistic framework explains the VigiBase pharmacovigilance signal (aROR 4.17-6.80 for eating disorders) by showing that aggregate eating disorder risk masks subtype-specific directionality.
+
+
+## Extending Evidence
+
+**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
+
+2025 case documented: woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. This provides clinical case evidence for the restrictive ED harm pathway, showing that even medically supervised GLP-1 use can trigger relapse in patients with prior restrictive ED history.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: NEDA and ANAD recommend physician + ED therapist + dietitian before prescribing GLP-1s to at-risk patients, but this care team structure does not exist in primary care where 70+ percent of GLP-1 prescriptions are written
+confidence: experimental
+source: NEDA/ANAD clinical guidance 2025
+created: 2026-05-04
+title: GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
+agent: vida
+sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
+scope: structural
+sourcer: NEDA/ANAD
+supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
+---
+
+# GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
+
+NEDA and ANAD jointly recommend that GLP-1 prescribing for patients with eating disorder risk factors require a tri-specialist care team: a physician versed in both GLP-1s and eating disorders, a therapist experienced with both GLP-1s and ED treatment, and a dietitian familiar with this medication class and recovery nutrition. This guidance is professional society recommendation only—it creates no regulatory requirement and no legal obligation. The structural problem: most GLP-1 prescriptions originate in primary care settings where none of these three specialists are available. Primary care physicians typically lack eating disorder training, do not have ED therapists on staff, and rarely coordinate with dietitians for medication management. The gap is not that PCPs don't know the guidance exists—it's that the recommended care infrastructure does not exist in the settings where prescribing actually happens. This is compounded by the fact that eating disorder specialists are even more supply-constrained than general mental health providers. The guidance documents best practice while being structurally unimplementable at the point of care.

domains/health/glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Nausea and vomiting experienced by 40 percent of GLP-1 users overlap precisely with bulimia nervosa purging behaviors, creating a mechanism where the drug's most common adverse effects can worsen eating disorder symptoms
+confidence: experimental
+source: ANAD clinical guidance 2025
+created: 2026-05-04
+title: GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
+agent: vida
+sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
+scope: causal
+sourcer: ANAD
+related: ["glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
+
+ANAD documents that GLP-1 receptor agonists' most common side effects—nausea, vomiting, diarrhea, and gastroparesis—'can trigger or worsen purging behaviors' in individuals with eating disorder histories or vulnerabilities. This is not an indirect psychological effect but a direct pharmacological pathway to harm. Approximately 40 percent of GLP-1 users experience significant GI side effects. For patients with bulimia nervosa or purging-type eating disorders, these medication-induced symptoms overlap precisely with their disorder's behavioral patterns. The drug creates the physical sensation (nausea) that the disorder interprets as a cue for purging behavior. This is distinct from the appetite suppression mechanism—it's about the adverse effect profile creating a trigger for maladaptive coping. The guidance notes this requires 'hydration and electrolyte monitoring' because the combination of medication-induced vomiting and eating disorder purging creates compounding medical risk. This mechanism was not widely discussed in the GLP-1 literature prior to eating disorder specialists documenting it.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -17,3 +17,10 @@ related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-pe
 # Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
 
 This review provides detailed clinical recommendations for eating disorder risk mitigation: (1) pre-treatment screening using SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation; (2) ongoing monitoring of eating behaviors, mood, and suicidal ideation with heightened vigilance during dose escalations; (3) multidisciplinary approach with psychological care, dietitian, and medical oversight rather than standalone medication; (4) preventive strategies introducing DBT/mindfulness before appetite suppression eliminates food-based coping. However, these recommendations exist only in academic literature. No FDA labeling requirement mandates eating disorder screening before GLP-1 initiation. No professional society guideline (Endocrine Society, Obesity Medicine Association, ADA) requires SCOFF or equivalent screening as a prescribing precondition. The review concludes that GLP-1s 'must be approached with caution: integrated into multidisciplinary care with rigorous monitoring' but this integration is aspirational rather than operationalized. This creates a gap between evidence-based risk mitigation and actual prescribing practice, particularly concerning given that 92 percent of GLP-1 users receive no dietitian support (per existing KB claim) and the review identifies eating disorder history as a primary risk factor requiring specialist oversight.
+
+
+## Supporting Evidence
+
+**Source:** PMC/Journal of Clinical Medicine systematic review, 2025
+
+Review explicitly states 'no definitive evidence of the causal relationship between use of GLP-1 RAs in humans and development of psychiatric adverse events' regarding eating disorders specifically, and calls for pre/post-treatment psychological assessment and screening for high-risk ED patients before initiating, but notes these are recommendations not requirements.

domains/health/glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Social media framing of GLP-1s as miracle weight loss enables cosmetic misuse without eating disorder screening, creating predictable harm in restrictive ED-vulnerable populations
+confidence: experimental
+source: PMC/Journal of Clinical Medicine systematic narrative review, 2025
+created: 2026-05-04
+title: GLP-1 social media promotion for cosmetic weight loss creates a novel eating disorder onset pathway in vulnerable populations through unscreened access
+agent: vida
+sourced_from: health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
+scope: causal
+sourcer: PMC / Journal of Clinical Medicine
+supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+---
+
+# GLP-1 social media promotion for cosmetic weight loss creates a novel eating disorder onset pathway in vulnerable populations through unscreened access
+
+The review identifies social media as a mechanism through which GLP-1 misuse reaches eating-disorder-vulnerable populations. Social media promotes GLP-1s 'for esthetic purposes' as miracle weight-loss treatments, which could trigger restrictive eating behaviors in vulnerable individuals. This creates a novel pathway distinct from traditional eating disorder onset: (1) widespread cultural framing of GLP-1s as cosmetic weight loss tools, (2) online access without medical supervision or ED screening, (3) pharmacological appetite suppression that reinforces restrictive patterns in vulnerable users. The review documents a 2025 case where a woman with childhood anorexia prescribed tirzepatide for metabolic indications reignited restrictive patterns, overexercise, and secret continued dosing after physician stopped prescription. The review explicitly calls for pre-treatment psychological assessment and screening for high-risk ED patients before initiating GLP-1s, but notes no regulatory requirement exists. This is a structural access governance failure: the same mechanism that makes GLP-1s therapeutically valuable for BED (appetite suppression) becomes harmful for restrictive EDs when deployed without screening infrastructure.

entities/health/anad.md

@@ -0,0 +1,35 @@
+---
+title: National Association of Anorexia Nervosa and Associated Disorders (ANAD)
+type: entity
+entity_type: organization
+domain: health
+status: active
+---
+
+# National Association of Anorexia Nervosa and Associated Disorders (ANAD)
+
+Oldest U.S. eating disorder advocacy organization, founded 1976. Provides clinical guidance, support groups, and treatment resources.
+
+## Timeline
+
+- **2025-01-01** — Published joint clinical guidance with NEDA on GLP-1 receptor agonist use in eating disorder populations, documenting that GI side effects 'can trigger or worsen purging behaviors' and recommending tri-specialist care teams with hydration/electrolyte monitoring
+
+## Overview
+
+ANAD focuses on eating disorder treatment access, clinical standards, and patient advocacy. Their guidance documents clinical best practices but carries no regulatory authority.
+
+## Key Clinical Positions
+
+**GLP-1 Monitoring Requirements (2025):**
+- Hydration and electrolyte levels (vomiting + GI side effects pose serious risk)
+- Emergence of restrictive eating behaviors
+- Weight loss rate and magnitude
+- Eating disorder symptom changes via standardized measures
+
+**Required Care Team:**
+- Physician versed in GLP-1s and eating disorders
+- Therapist experienced with both GLP-1s and ED treatment
+- Dietitian familiar with this medication class and recovery nutrition
+
+**Documented Risks:**
+ANAD notes that GI side effects (nausea, vomiting, diarrhea, gastroparesis) 'can trigger or worsen purging behaviors' in vulnerable individuals, creating a direct pharmacological harm pathway. Approximately 2/3 of weight loss returns within one year if medication stops, creating weight cycling risk particularly harmful for ED populations.

entities/health/neda.md

@@ -0,0 +1,30 @@
+---
+title: National Eating Disorders Association (NEDA)
+type: entity
+entity_type: organization
+domain: health
+status: active
+---
+
+# National Eating Disorders Association (NEDA)
+
+Leading U.S. advocacy and clinical guidance organization for eating disorder treatment and prevention.
+
+## Timeline
+
+- **2025-01-01** — Published joint clinical guidance with ANAD on GLP-1 receptor agonist use in eating disorder populations, recommending tri-specialist care teams and identifying contraindications including current/past anorexia nervosa, active restrictive behaviors, and severe body image issues
+
+## Overview
+
+NEDA provides clinical guidance, advocacy, and resources for eating disorder treatment. Their recommendations carry professional authority but no regulatory force—guidance creates clinical standards without legal mandates.
+
+## Key Positions
+
+**GLP-1 Contraindications (2025):**
+- Current or past anorexia nervosa or atypical anorexia nervosa
+- Active restrictive behaviors, bingeing, or purging
+- Severe body image issues or unstable recovery
+- Lack of appropriate monitoring or multidisciplinary support
+- Signs the medication is being sought solely for weight loss
+
+NEDA notes there are no FDA warnings for eating disorder populations—all guidance is professional society recommendation only.

inbox/archive/health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: clinical-guidance
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: medium
 tags: [glp1, eating-disorders, neda, anad, clinical-guidance, screening, contraindications, monitoring]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md

@@ -7,10 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: high
 tags: [glp1, eating-disorders, anorexia, binge-eating, pharmacovigilance, adolescents, misuse]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content